RxSight faces a critical inflection point as revenue growth has reversed from a 77.6% peak in 2023Q4 to a 18.5% contraction in 2026Q1, signaling potential saturation or structural headwinds in its specialized ophthalmic market. While the company maintains a ro...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.29+12.0% vs -$0.33 | $34M+3.7% vs $33M |
Q2 2026 May 6, 2026 | -$0.38-27.1% vs -$0.30 | $31M+3.8% vs $30M |
Q1 2026 Feb 25, 2026 | -$0.22+34.3% vs -$0.33 | $33M+8.1% vs $30M |
Q4 2025 Nov 5, 2025 | -$0.24+29.4% vs -$0.34 | $30M+19.9% vs $25M |
Corient Private Wealth LP bought a new stake in shares of RxSight, Inc. (NASDAQ: RXST) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 85,838 shares of the company's stock, valued at approximately $414,000. Corient Private Wealth LP owned 0.21% of RxSight at the
BlackRock Inc. acquired a new stake in RxSight, Inc. (NASDAQ: RXST) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,790,408 shares of the company's stock, valued at approximately $27,910,000. BlackRock Inc. owned 13.99% of RxSight at the end
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.
RxSight (NASDAQ: RXST - Get Free Report) and Futureworld (OTCMKTS:FWDG - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Risk and Volatility RxSight has a beta of 1.13, suggesting
Benchmark RXST against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for RxSight, Inc. (RXST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.85 | $200.77M | -5.11 | -3.89% | -28.96% | -13.99% | — | |
| $80.58 | $1.84B | 31.98 | 13.53% | 25.02% | 16.42% | — | |
| $59.96 | $3.05B | -249.81 | 14.88% | 1.85% | 2.14% | — | |
| $111.75 | $3.67B | -80.40 | 26.24% | -1.69% | -8.97% | — | |
| $87.00 | $3.01B | 17.86 | 37.13% | 22.69% | 32.97% | — | |
| $148.17 | $10.61B | 26.22 | 0.9% | 9.99% | 10.09% | — |
RxSight, Inc. (RXST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
RxSight, Inc. (RXST) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 15, 2026·SEC
Jul 6, 2026·SEC
Get notified when RXST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RxSight, Inc. (RXST) stock FAQ — growth, dividends, profitability & financials explained
RxSight, Inc. (RXST) reported $127.6M in revenue for fiscal year 2025. This represents a 5593% increase from $2.2M in 2019.
RxSight, Inc. (RXST) saw revenue decline by 3.9% over the past year.
RxSight, Inc. (RXST) reported a net loss of $46.9M for fiscal year 2025.
RxSight, Inc. (RXST) has a return on equity (ROE) of -14.0%. Negative ROE indicates the company is unprofitable.
RxSight, Inc. (RXST) had negative free cash flow of $38.8M in fiscal year 2025, likely due to heavy capital investments.
